Immunotherapy for early triple negative breast cancer: research agenda for the next decade

Immunotherapy for early triple negative breast cancer: research agenda for the next decade

For decades, the systemic treatment of localized triple negative breast cancer (TNBC) has exclusively relied on chemotherapy. Recent advancements, however, are rapidly reshaping the treatment algorithms for this disease. The addition of pembrolizumab to neoadjuvant chemotherapy has indeed shown to s...

Full description

Bibliographic Details
Main Authors: Andrè, F. (Author), Bianchini, G. (Author), Cortes, J. (Author), Corti, C. (Author), Curigliano, G. (Author), Mittendorf, E.A (Author), Rugo, H. (Author), Schmid, P. (Author), Tarantino, P. (Author), Tolaney, S.M (Author)
Format: Article
Language:English
Published: Nature Research 2022
Subjects:
adjuvant therapy
anthracycline
antiapoptotic activity
antibody drug conjugate
atezolizumab
biological marker
breast cancer
cancer chemotherapy
cancer immunotherapy
cancer prognosis
capecitabine
carboplatin
circulating tumor DNA
colitis
cyclophosphamide
disease exacerbation
disease free survival
distant disease free survival
durvalumab
estrogen receptor
event free survival
financial distress
hepatitis
HLA system
hormone receptor positive breast cancer
hyperthyroidism
hypophysitis
hypothyroidism
immune checkpoint inhibitor
major histocompatibility antigen class 1
major histocompatibility antigen class 2
minimal residual disease
neoadjuvant chemotherapy
nonhuman
olaparib
overall survival
paclitaxel
pembrolizumab
placebo
pneumonia
programmed death 1 ligand 1
Review
sacituzumab govitecan
skin toxicity
survival analysis
taxane derivative
therapy escalation
triple negative breast cancer
tumor associated leukocyte
tumor mutational burden
veliparib
Online Access:View Fulltext in Publisher

Internet

View Fulltext in Publisher

Similar Items